Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and Company : - Anat Hakim to join Lilly as General Counsel

share with twitter share with LinkedIn share with facebook
01/27/2020 | 08:29am EDT

INDIANAPOLIS - Eli Lilly and Company (NYSE: LLY) announced today that Anat Hakim will join the company on February 3, 2020 as senior vice-president and general counsel.

Hakim succeeds Michael J. Harrington who will retire on January 31, 2020.

'I am excited to welcome Anat to Lilly as our new general counsel,' said David A. Ricks, Lilly's chairman and CEO. 'Anat's legal expertise and prior experiences in the pharmaceutical industry, across healthcare more broadly, and as general counsel at WellCare Health Plans make her the ideal person to lead Lilly's law division. I look forward to the external perspective and informed legal opinion that she will bring to our executive team as we continue to progress our innovation-based strategy and develop new medicines for patients around the world.'

Hakim most recently served as executive vice president, general counsel and secretary at WellCare Health Plans, where she provided strategic counsel on a broad range of legal, business and operational matters for the company and its board of directors. She was recently recognized as General Counsel of the Year in 2019 by Corporate Counsel. Before WellCare, Hakim served as divisional vice president, associate general counsel for intellectual property litigation at Abbott Laboratories, and later as the company's divisional vice president, associate general counsel for litigation. She began her career at Latham Watkins after earning her law degree from Harvard University, and also worked for 12 years at Foley & Lardner LLP.

'The legal team at Lilly is incredibly talented and is trusted to provide expert counsel to all aspects of the company's operations,' Hakim said. 'I'm thrilled to lead the law division and to be joining Lilly at such an exciting time for the company. Lilly's focus on innovation, its promising pipeline of new medicines, and its desire to make medicines more affordable for patients make it the ideal place for me. I can't wait to get started.'

Ricks also commented, 'I want to take this opportunity to again thank Mike Harrington for his significant contributions throughout his time at Lilly. Over the past eight years, Mike has very successfully led our legal organization and was a great partner to me and the Lilly Board of Directors. We are grateful for his leadership and wish him well in this next chapter of his life.'

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

This press release contains forward-looking statements about leadership changes and reflects Lilly's current beliefs. There are risks and uncertainties related to leadership changes. Lilly undertakes no duty to update forward-looking statements.


Kevin Hern

Tel: (317) 277-1838

Email: hernkevinr@lilly.com

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY -2.27% 142.8 Delayed Quote.11.18%
share with twitter share with LinkedIn share with facebook
05:52pGLANCY PRONGAY & MURRAY LLP : a Leading Securities Fraud Law Firm, Continues Inv..
12:16pELI LILLY AND : Lilly Declares Fourth-Quarter 2020 Dividend
12:12pWHO says expects to hear more soon on paused COVID-19 antibody trial
09:02aELI LILLY : Health Canada Approves Taltz for Non-Radiographic Axial Spondyloarth..
10/18SHANGHAI JUNSHI BIOSCIENCES : May Benefit From Covid-19 Neutralising Antibody
10/16ELI LILLY AND COMPANY : - Lilly Announces Agreement to Acquire Disarm Therapeuti..
10/15Gilead questions WHO study that cast doubts on drug's COVID-19 benefits
10/15INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claim..
10/15ELI LILLY AND : to Buy Disarm Therapeutics for Initial $135 Million
10/15ELI LILLY AND : Lilly Announces Agreement to Acquire Disarm Therapeutics
More news
Financials (USD)
Sales 2020 23 807 M - -
Net income 2020 6 101 M - -
Net Debt 2020 11 592 M - -
P/E ratio 2020 22,2x
Yield 2020 2,04%
Capitalization 132 B 132 B -
EV / Sales 2020 6,05x
EV / Sales 2021 5,44x
Nbr of Employees 33 625
Free-Float 99,8%
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 166,47 $
Last Close Price 146,12 $
Spread / Highest target 36,9%
Spread / Average Target 13,9%
Spread / Lowest Target -17,9%
EPS Revisions
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.53%389 921
ROCHE HOLDING AG-0.56%291 357
PFIZER INC.-3.14%210 884
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-14.09%190 074